MGI Tech Co.,?has formed a strategic partnership with Dasa, Latin America?s largest medical diagnostics company, to enhance access to advanced genomic technologies for patients in Brazil and advance the country's healthcare sector.

BayCare has begun construction on the Tampa Bay area's first proton therapy center, which will be located at the BayCare Cancer Institute within St. Joseph's Hospital. The facility is expected to start treating patients in 2025

ICardio.ai, a Los Angeles-based company specializing in machine learning and deep learning algorithms for ultrasound analysis, is partnering with Abbott.

Muse? by Interaxon, a prominent player in brain health and neurotechnology, has introduced Alpha Peak, a new metric designed to assess cognitive performance. This metric is the first

Piccolo Medical, Inc. (Piccolo) has received FDA clearance to market its PM2? System with ECGuide? Connector. This new catheter guidance technology expands Piccolo's portfolio of products designed to reduce

Exact Sciences Corp.? has released new performance data for its blood-based colorectal cancer (CRC) screening test. The results indicate an 88.3% sensitivity for CRC and 31.2% for advanced precancerous lesions,

Synchron, a leading brain-computer interface (BCI) company, has achieved a notable milestone with the first use of Amazon?s Alexa by a patient implanted with Synchron?s BCI technology. Mark, a 64-year-old man with amyotrophic lateral sclerosis

Remedee Labs, a French start-up focused on non-pharmacological treatments for chronic pain, has announced that its millimeter wave endorphin stimulator wristband has officially been granted medical device status in Europe.

King Faisal Specialist Hospital & Research Centre recently achieved a major medical milestone by performing the world?s first fully robotic heart transplant on a 16-year-old patient with end-stage heart failure.

Neuraptive Therapeutics has announced that its investigational drug, NTX-001, has been granted Breakthrough Therapy Designation by the FDA. This designation could significantly speed up the development process for this therapy